R&D Trends

Myos, Cloud Pharmaceuticals ink agreement

Friday, July 18, 2014 01:32 PM

Myos, a biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, has entered into an R&D agreement with Cloud Pharmaceuticals.

More... »

WIRB Copernicus Group

Seven U.K. research councils collaborate on antimicrobial resistance

Thursday, July 17, 2014 12:50 PM

The Medical Research Council (MRC) will lead an initiative of seven research councils, backed by eight government bodies and the Wellcome Trust, to tackle antimicrobial resistance (AMR) on all fronts. The seven research councils are the Arts and Humanities Research Council, Biotechnology and Biological Sciences Research Council, Economic and Social Research Council, Engineering and Physical Sciences Research Council, MRC, Natural Environment Research Council and Science and Technology Facilities Council.

More... »

CRF Health eCOA webinar series

Life Sciences Hub Wales launched

Thursday, July 17, 2014 12:45 PM

The Welsh government has launched the Life Sciences Hub Wales, a national and international focal point for the life sciences and healthcare sectors in Wales. The life sciences hub will be based in Cardiff Bay and will bring together academic, business, clinical, professional services and funding organizations.

More... »

Eli Lilly, Immunocore collaborate for novel cancer therapies

Wednesday, July 16, 2014 01:15 PM

Eli Lilly and Immunocore, a privately owned, clinical-stage biotechnology company, have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies.

More... »

CEL-SCI receives $225,000 NIH research grant

Wednesday, July 16, 2014 01:11 PM

CEL-SCI has been awarded a phase I Small Business Innovation Research (SBIR) grant for $225,000 from the National Institute of Arthritis Muscoskeletal and Skin Diseases (NIAMS), part of the NIH. The grant will fund the further development of CEL-SCI’s LEAPS technology as a potential treatment for rheumatoid arthritis (RA), an autoimmune disease of the joints. According to Visiongain, the world RA drug market will generate revenues of $38.5 billion in 2017.

More... »

HD Biosciences partners with Marshall University

Monday, July 14, 2014 12:45 PM

HD Biosciences (HDB), a Shanghai-based, biology-focused preclinical drug discovery CRO, the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine have announced a new partnership to co-develop potential anti-cancer drugs.

More... »

Report: Orphan drug approvals up, but high costs pose challenges for patients

Friday, July 11, 2014 02:02 PM

Although the pace of approvals for new orphan drugs—medicines that treat relatively rare conditions—have increased in the U.S. and Europe in recent years, patients are facing growing challenges accessing those drugs, a newly completed study by the Tufts Center for the Study of Drug Development (CSDD) at Tufts University has concluded.

More... »

Survey shows support for increased stem cell research

Thursday, July 10, 2014 12:48 PM

Americans are in broad support of more stem cell research, according to the results of an online survey released by Cord Blood Registry (CBR) to coincide with National Cord Blood Awareness Month.

More... »

VC investment in healthcare sector soars in second quarter

Thursday, July 10, 2014 06:03 AM

By Ronald Rosenberg
CenterWatch Staff Writer

More than 50% of all initial public offerings in the second quarter of 2014 were healthcare companies, as 24 venture capital-backed firms became publicly traded, compared to a more robust first quarter of 35 IPOs. 

More... »

Sorrento awarded up to $2.6M from NIH for bispecific antibodies

Wednesday, July 9, 2014 12:12 PM

Sorrento Therapeutics, a late-stage clinical oncology company developing new treatments for cancer and its associated pain, has received two NIH small business grants, which will fund the development of bispecific antibodies for two of its anti-bacterial immunotherapies. Sorrento's highly diverse, fully human G-MAB library and proprietary antibody conjugation technology platforms have broad applications beyond oncology, including other therapeutic areas such as anti-infectives and auto-immune diseases.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs